Literature DB >> 15210852

Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells.

Alessandro Salvi1, Bruna Arici, Giuseppina De Petro, Sergio Barlati.   

Abstract

The serine protease urokinase-type plasminogen activator (u-PA) is involved in a variety of physiologic and pathological processes; in particular, u-PA mRNA is up-regulated in human hepatocellular carcinoma (HCC) biopsies and its level of expression is inversely correlated with patients' survival. To determine the role of u-PA in the invasiveness properties of HCC, we successfully down-regulated u-PA by RNA interference (RNAi) technology, in an HCC-derived cell line at high level of u-PA expression. RNAi is a multistep process involving generation of small interfering RNAs (siRNA) that cause specific inhibition of the target gene. SKHep1C3 cells were transfected with a U6 promoter plasmid coding for an RNA composed of two identical 19-nucleotide sequence motifs in an inverted orientation, separated by a 9-bp spacer to form a hairpin dsRNA capable of mediating target u-PA inhibition. Stable transfectant cells showed a consistently decreased level of u-PA protein. In biological assays, siRNA u-PA-transfected cells showed a reduction of migration, invasion, and proliferation. In conclusion, u-PA down-regulation by RNAi technology decreases the invasive capability of HCC cells, demonstrating that stable expression of siRNA u-PA could potentially be an experimental approach for HCC gene therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210852

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  16 in total

1.  Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Authors:  Fan Lin; Yuyuan Li; Jie Cao; Shaofeng Fan; Jifeng Wen; Guanghui Zhu; Hong Du; Yanxiao Liang
Journal:  Mol Biol Rep       Date:  2010-12-29       Impact factor: 2.316

Review 2.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

3.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

4.  Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.

Authors:  Sai Murali Krishna Pulukuri; Bharathi Gorantla; Venkata Ramesh Dasari; Christopher S Gondi; Jasti S Rao
Journal:  Mol Cancer Res       Date:  2010-07-27       Impact factor: 5.852

5.  Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells.

Authors:  Alessandro Salvi; Italia Bongarzone; Francesca Miccichè; Bruna Arici; Sergio Barlati; Giuseppina De Petro
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 6.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.

Authors:  Sai Murali Krishna Pulukuri; Bharathi Gorantla; Jasti S Rao
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

9.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

10.  Correlation analysis of liver tumor-associated genes with liver regeneration.

Authors:  Cun-Shuan Xu; Shou-Bing Zhang; Xiao-Guang Chen; Salman Rahman
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.